$FCSC at resistance $2.35 in/out a 5-bagger corre
Post# of 36
(Total Views: 864)
Posted On: 04/15/2017 5:07:09 PM
$FCSC at resistance $2.35
in/out a 5-bagger corrected
since 8/9/14
off 10 day cross over 20 day on upper bollie
Website
Last ten trades
10-K 3/9/17
33% x 60% Buy
Ultra low float
Shares Outstanding 14.69M
Float 9.1M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 166.06k
Short Ratio 2.51
Short % of Float 1.24%
Shares Short (prior month) 162.59k
Stock technical analysis
News
and filings
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The companys gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
in/out a 5-bagger corrected
since 8/9/14
off 10 day cross over 20 day on upper bollie
Website
Last ten trades
10-K 3/9/17
33% x 60% Buy
Ultra low float
Shares Outstanding 14.69M
Float 9.1M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 166.06k
Short Ratio 2.51
Short % of Float 1.24%
Shares Short (prior month) 162.59k
Stock technical analysis
News
and filings
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The companys gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
(1)
(0)